Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cypher withdrawal issues resolved, says Johnson & Johnson

This article was originally published in Clinica

Executive Summary

Johnson & Johnson had already corrected by January 14 the manufacturing process that led to its voluntary withdrawal of 300 drug-eluting Cypher stents on January 13, a spokesperson for the company's Cordis business told Clinica. The single lot of devices was called back from 145 hospital accounts after six coronary stents were found during manufacturing auditing at a Puerto Rico production facility to have a reduced amount of polymer coating. The problem was immediately identified and corrective steps were taken, said the company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054038

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel